Australia's medical regulators have given a green light for a COVID vaccine that will target the Omicron variant.

The Therapeutic Goods Administration granted provisional approval to Moderna's bivalent COVID vaccine, the first of its type in Australia.

The bivalent vaccine will be able to trigger an immune response against the original COVID variant and the Omicron strain.

The vaccine has been approved for use as a booster among those over 18 and be given at least three months after the initial two doses or previous booster.

Final approval for the new vaccine will still need to be granted by the Australian Technical Advisory Group on Immunisation.

It comes as Australia's leading scientific organisation called for a boost to virus research and vaccine manufacturing capabilities in a bid to future-proof the country from pandemics.

In a new report, the CSIRO outlined 20 recommendations for what Australia would need to do to strengthen pandemic preparedness, following on from the experiences of COVID-19.

Among the recommendations were to improve research into five virus families that have the greatest potential to become future pandemics.

Scientists also identified a need to diversify the types of vaccines made in Australia to be better prepared.

"The absence of manufacturing capabilities across diverse vaccine technologies reduces Australia's capability to produce vaccines onshore for an emergent viral threat," the report said.

"Australian companies face barriers, such as high input costs and small population for clinical trial enrolments."

The CSIRO report also called for an expansion of screening for commercially available therapeutic antiviral medications that could be used as treatments, along with the creation of a central database of therapeutics.

The recommendations in the report came following discussions with more than 140 experts across industry, research and government areas.

The findings of the report also identified inconsistencies with diagnostic requirements, which needed to be diversified due to the increased demands on labs during pandemics.

A lack of national coordination on genomic analysis was also identified, with calls to set up a national authority, as well as developing national data standards.

"Australia faces data sharing limitations due to the varying governance of health systems within and across jurisdictions," the report said.

"This restricts policy decisions being made in a timely and well-informed manner, especially during pandemics."

The CSIRO said the report findings were critical, given the rise in viral disease outbreaks in the past century.

"On average, two novel viruses are appearing in humans each year, and the proportion that give rise to larger outbreaks is growing," the report said.

"The increasing occurrence of virus spill-over from animal populations over the last 100 years has largely been driven by environmental destruction, climate change, urbanisation, human encroachment on natural habitats, and increased global trade and travel."

There were more than 12,000 cases of COVID reported nationally on Tuesday along with a further 75 deaths from the virus.

LATEST 24-HOUR COVID-19 DATA:

Victoria: 2950 cases, 18 deaths, 337 in hospital with 22 in ICU

NSW: 4271 cases, 37 deaths, 1834 in hospital with 40 in ICU

QLD: 2404 cases, 18 deaths, 319 in hospital with 10 in ICU

WA: 1277 cases, one death, 234 in hospital with five in ICU

SA: 685 cases, three deaths, 129 in hospital with seven in ICU

Tasmania: 259 cases, no deaths, 30 in hospital with one in ICU

ACT: 202 cases, no deaths, 100 in hospital with one in ICU

NT: 116 cases, no deaths, 21 in hospital with none in ICU.